CVS’ efforts to reform how its pharmacies are paid have reached a significant milestone that should stabilize flagging margins.

CVS Health's Medicaid business is experiencing medical cost pressure from higher-than-expected acuity following the ...

Allen Lutz, an analyst from Bank of America Securities, maintained the Buy rating on CVS Health (CVS – Research Report). The associated price ...

A state law that went into effect this week aims to regulate the role of third-party pharmacy benefit managers, who many say ...

CVS Health's Medicaid business ... aware of how big pharma profits from high drug prices, but few understand the market distortions introduced by pharmacy benefit management (PBM) companies ...

Just more than five years ago, the Minnesota Legislature attempted to rein in the oft-critiqued PBM industry by passing a law that allowed the state to regulate the companies to protect consumers and ...

Multiple reports indicate that employers can expect rising healthcare costs in 2025. To address these costs, employers are ...

The latest trading session saw CVS Health (CVS) ending at $45.78, denoting a -0.09% adjustment from its last day's close. This change was narrower than the S&P 500's 1.11% loss on the day. Meanwhile, ...

Pharmacy benefit managers negotiate drug costs with pharmacies ... 502.07 in afternoon trading. "CVS leverages free-market competition to fight back against pharma price gouging, and we are ...

Americans seeking care report delaying or forgoing treatment because of the “administrative burdens” of dealing with health ...

BMO analyst Kelly Bania said the numbers suggested underlying grocery trends are weak and that the company is losing market share. BMO has a market-perform, or neutral, rating on the stock and a $19 ...

CVS' Aetna sues drug manufacturers for price-fixing and market allocation scheme. The subsidiary seeks damages and ...